Incentives for biodefense countermeasure development

Biosecurity and Bioterrorism

Volumn 5, Issue 3, 2007, Pages 228-238

  Matheny, Jason ^a   Mair, Michael ^a   Mulcahy, Andrew ^b   Smith, Bradley T ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOLOGICAL WARFARE; DRUG INDUSTRY; ECONOMICS; HUMAN; MOTIVATION; POLITICS; RESEARCH; UNITED STATES;

BIOTERRORISM; DRUG INDUSTRY; HUMANS; MOTIVATION; POLITICS; RESEARCH; UNITED STATES;

EID: 38449094229     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2007.0030     Document Type: Article

References (62)

1. Parker G. HHS Public Health Emergency Medical Countermeasures Enterprise Strategy for Chemical, Biological, Radiological and Nuclear Threats. Federal Regist 2007;72(53): 13109-13114.
2. Parker G. HHS Public Health Emergency Medical Countermeasures Enterprise Implementation Plan for Chemical, Biological, Radiological and Nuclear Threats. Federal Regist 2007;72(77):20117-20128.
3. Bush G. Homeland Security Presidential Directive 18. Washington, DC: The White House; 2007.
4. Bush G. Homeland Security Presidential Directive 10. Washington, DC: The White House; 2004.
5. O'Toole T, Inglesby TV. Toward biosecurity. Biosecur Bioterror 2003;1(1):1.
6. Gilfillan L, Smith BT, Inglesby TV, et al. Taking the measure of countermeasures: leaders' views on the nation's capacity to develop biodefense countermeasures. Biosecur Bioterror 2004; 2(4):320-327.
7. DeFrancesco L. Throwing money at biodefense. Nat Biotechnol 2004 Apr;22(4):375-378.
8. Lam C, Franco C, Schuler A. Billions for biodefense: federal agency biodefense funding, FY2006-2007. Biosecur Bioterror 2006;4(2):113-127.
9. Trull MC, du Laney TV, Dibner MD. Turning biodefense dollars into products. Nat Biotechnol 2007 Feb;25(2):179-184.
10. Project BioShield: Annual Report to Congress. Washington, DC: U.S. Department of Health and Human Services, 2006.
11. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003 Mar;22(2):151-185.
12. Adams CP, Brantner W. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006 Mar-Apr;25(2):420-428.
13. Medicines in Development for Infectious Diseases. Washington, DC: Pharmaceutical Research and Manufacturers of America; 2004.
14. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004 Aug;3(8):711-715.
15. Grabowski H. Increasing R&D incentives for neglected diseases: lessons from the Orphan Drug Act. In: Maskus KE, Reichman JH, eds. International Public Goods and Transfer of Technology under a Globalized Intellectual Property Regime. Cambridge, UK: Cambridge University Press; 2005:457-480.
16. Hartmann M, Hassan A. Application of real options analysis for pharmaceutical R&D project valuation - empirical results from a survey. Research Policy 2006;35(3):343-354.
17. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004 May 1;38(9):1279-1286.
18. Christoffersen RE. Antibiotics - an investment worth making? Nat Biotechnol 2006 Dec;24(12):1512-1514.
19. Altman S, Bassler BL, Beckwith J, et al. An open letter to Elias Zerhouni. Science 2005 Mar 4;307(5714):1409.
20. Kresse H, Belsey MJ, Rovini H. The antibacterial drugs market. Nat Rev Drug Discov 2007;6:19-20.
21. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007 Jan;6(1):29-40.
22. Offit PA. Why are pharmaceutical companies gradually abandoning vaccines? Health Aff (Millwood) 2005 May-Jun; 24(3):622-630.
23. Kremer M, Synder CM. Why Are Drugs More Profitable than Vaccines? NBER Working Paper 9833. Cambridge, MA: National Bureau of Economic Research; 2003.
24. Coleman MS, Sangrujee N, Zhou F, Chu S. Factors affecting U.S. manufacturers' decisions to produce vaccines. Health Aff (Millwood) 2005 May-Jun;24(3):635-642.
25. DiMasi JA, Grabowski H, Vernon J. R&D costs and returns by therapeutic category. Drug Inf J 2004;38(3):211-224.
26. Finkelstein A. Health Policy and Technological Change: Evidence from the Vaccine Industry. NBER Working Paper 9460. Cambridge, MA: National Bureau of Economic Research; 2003.
27. Struck MM. Vaccine R&D success rates and development times. Nat Biotechnol 1996;14:591-593.
28. Kaitin KI. Number of vaccines entering clinical study rose only modestly since 1990s. Tufts Center for the Study of Drug Development: Impact Report 2006;8(4):3.
29. Zimmerman D, Rosenthal K, Talor E. The vaccine conundrum. Scientist 2007;21(4):48.
30. U.S. Food and Drug Administration. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Federal Regist 2002 May 31;67(105): 37988.
31. Gronvall GK, Trent D, Borio LL, et al. The FDA Animal Efficacy Rule and biodefense countermeasures: a way forward. Nat Biotechnol. In press.
32. Halpern NA, Pastores SM, Greenstein RJ. Critical care medicine in the United States 1985-2000: an analysis of bed numbers, use, and costs. Crit Care Med 2004 Jun;32(6): 1254-1259.
33. Smith BT, Inglesby TV, O'Toole T. Biodefense R&D: anticipating future threats, establishing a strategic environment. Biosecur Bioterror 2003;1(3):193-202.
34. Borio LL, Gronvall GK. Anthrax countermeasures: current status and future needs. Biosecur Bioterror 2005;3(2):102-117
35. National Institutes of Health, Office of Technology Transfer. Annual Report Fiscal Year 2005. Rockville, MD: NIH; 2005.
36. Scarpa T. Research funding: peer review at NIH. Science 2006 Jan 6;311(5757):41.
37. National Institutes of Health, Office of Technology Transfer. Frequently Asked Questions: CRADAs & MTAs. Rockville, MD: NIH; 2006.
38. National Institute of Allergy and Infectious Diseases. NIAID Biodefense Resources. 2007. http://www3.niaid.nih.gov/Biodefense/Research/ resources.htm. Accessed August 24, 2007.
39. Bloom N, Griffith R, Van Reenen J. Do R&D tax credits work? Evidence from a panel of countries 1979-1997. J Public Econ 2002;85:1-31.
40. Audretsch DB, Bozeman B, Combs KL, et al. The economics of science and technology. J Technol Transf 2002;27:155-203.
41. Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Aff (Millwood) 2006 Mar-Apr; 25 (2):313-324.
42. Towse A. A Review of IP and Non-IP Incentives for R&D for Diseases of Poverty. What Type of Innovation Is Required and How Can We Incentivise the Private Sector to Deliver It? Geneva: World Health Organization: Commission on Intellectual Property Rights, Innovation and Public Health; 2005.
43. Hsu JC, Schwartz ES. Model of R&D Valuation and the Design of Research Incentives. Cambridge, MA: National Bureau of Economic Research; 2003.
44. Cook-Deegan R. Does NIH need a DARPA? Issues Sci Technol 1996; Winter. http://www.issues.org/13.2/cookde.htm. Accessed August 9, 2007.
45. Roy R. Funding science: the real defects of peer review and an alternative to it. Sci Technol Human Values 1985;10(3): 73-81.
46. Sommer J. A radical proposal for reorganizing research support: lotteries, prizes. Scientist 1991 June 10;5(12):11,13,17.
47. Hanson R. Comparing peer review to information prizes - a possible economics experiment. Social Epistemology 1995; 9(1):49-55.
48. Tsao J. Consumer preferences and funding priorities in scientific research. Sci Public Policy 1989;16(5):294-298.
49. U.S. Senate Judiciary Committee and U.S. Senate Health, Education, Labor, and Pensions Committee Hold Joint Hearing on BioShield Drugs. Congressional Quarterly 6 October 2004.
50. National Research Council. Innovation Inducement Prizes at the National Science Foundation. Washington, DC: National Academies Press; 2007.
51. Gallini N, Scotchmer S. Intellectual property: when is it the best incentive mechanism? Innovation Policy and the Economy 2001;2:51-78.
52. Berndt ER, Glennerster R, Kremer MR, et al. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ 2007 May;16(5): 491-511.
53. Arnst C. Vaccinating the world. Business Week 9 February 2007.
54. Berndt ER, Hurvitz JA. Vaccine advance-purchase agreements for low-income countries: practical issues. Health Aff (Millwood) 2005 May-Jun;24(3):653-665.
55. Farlow AWK, Light DW, Mahoney RT, et al. Concerns regarding the Center for Global Development Report "Making Markets for Vaccines." Geneva: Commission on Intellectual Property Rights, Innovation and Public Health; 2005.
56. Gronvall GK, Smith BT, Matheny J, et al. Meeting report: Biomedical Advanced Research and Development Authority (BARDA) roundtable. Biosecur Bioterror 2007; 5(2):174-179.
57. Petro JB, Plasse TR, McNulty JA. Biotechnology: impact on biological warfare and biodefense. Biosecur Bioterror 2003; 1(3):161-168.
58. Gronvall GK, Matheny J, Smith BT, et al. Flexible defenses roundtable meeting: promoting the strategic innovation of medical countermeasures. Biosecur Bioterror 2007;5(3):271-277.
59. Maurer SM. Choosing the right incentive strategy for research and development in neglected diseases. Bull World Health Organ 2006 May;84(5):376-381.
60. Munos B. Can open-source R&D reinvigorate drug research? Nat Rev Drug Discov 2006 Sep;5(9):723-729.
61. Grace C. Developing New Technologies to Address Neglected Diseases: The Role of Product Development Partnerships and Advanced Market Commitments. London: United Kingdom, Department for International Development (DFID) Health Resource Centre; 2006.
62. Hoyt K. Vaccine innovation: lessons from World War II. J Public Health Policy 2006;27(1):38-57; discussion 58-60.